References
- Mehrmal S, Uppal P, Nedley N, et al. The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: a systematic analysis from the global burden of disease study 2017. J Am Acad Dermatol. 2021;84(1):46–52.
- Damiani G, Cazzaniga S, Conic RRZ, et al. Pruritus characteristics IN A LARGE ITALIAN COHORT OF PSORIATIC PATIENTS. J Eur Acad Dermatol Venereol. 2019;33(7):1316–1324.
- Nast A, Boehncke W-H, Mrowietz U, et al. S3 – Guidelines on the treatment of psoriasis vulgaris (English version). J Der Deutsch Dermatol Gesellschaft. 2012;10:S1–s95.
- Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23:1–70.
- Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. IJMS. 2019;20(6):1475.
- Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol. 2014;70(5):871–881.
- Bronsard V, Paul C, Prey S, et al. What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24(2):17–22.
- Schaarschmidt ML, Umar N, Schmieder A, et al. Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol. 2013;27(2):187–198.
- Richards HL, Fortune DG, O'Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41(4):581–583.
- Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136–139.
- Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013;149(10):1180–1185.
- Korman NJ, Zhao Y, Pike J, et al. Satisfaction with current psoriasis treatment: misalignment between physician and patient perceptions. Dermatol Online J. 2016;15(22(7):13030.
- Storm A, Andersen SE, Benfeldt E, et al. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59(1):27–33.
- Strober B, Bagel J, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study. J Drugs Dermatol. 2017;16(8):801–808.
- Papadavid E, Rompoti N, Theodoropoulos K, et al. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018;32(7):1173–1179.
- Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.
- Finlay AY, Khan GK. Dermatology life quality index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216.
- Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol. 2010;24:10–16.
- R Core Team. R: a language and environment for statistical computing. R foundation for statistical computing. Vienna, Austria: R Core Team; 2019.
- Schaarschmidt ML, Kromer C, Herr R, et al. Treatment satisfaction of patients with psoriasis. Acta Derm Venerol. 2015;95(5):572–578.
- Poulin Y, Papp KA, Wasel NR, et al. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. Int J Dermatol. 2010;49(12):1368–1375.